| INTRODUCTION
Adenoid cystic carcinoma (ACC) is a rare head and neck cancer with about 500 new patients in the USA every year. 1 ACC most often arise from the salivary glands, affecting most commonly the minor but also the major salivary glands of the head and neck. 2 Furthermore, ACC originating from the external auditory canal or the thyroid as well as trachea has been described. 3, 4 Although the tumor is well-differentiated, slow tumor growth regularly delays the diagnosis and treatment. 5, 6 Perineural spread can be frequently observed, making a complete radical resection of the primary tumor in combination with postoperative radiotherapy the main therapeutic approach. As complete surgical tumor removal is challenging, locoregional recurrence is common. 7, 8 If surgery is not feasible, primary radiation is the only treatment option. 9, 10 Exclusive systemic chemotherapy has very limited effects and has been only evaluated in selected clinical trials so far. 11 Late diagnosis of local recurrence goes hand in hand with poor long-term survival rates. A 15-year survival rate of 40% reflects the prolonged course of metastatic disease and late local recurrences. 12 Regular follow-up after primary tumor treatment is mandatory as early detection of local recurrence may have a significant impact on patient survival. Here, especially the detection of local recurrence and differentiation between posttherapeutic alterations and vital tumor is particularly difficult. Therefore, MRI is considered the method of choice in clinical practice by providing high morphological information of the head and neck structures, allowing the reliable detection of perineural tumor spread and bone marrow infiltration. 13 Tumor staging accuracy can be considerately increased by 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography/computed tomography (PET/CT) in squamous cell carcinoma of the head and neck, 14 but no studies investigating a sole ACC cohort in PET(/CT) are published so far. Thus, the role of hybrid imaging in ACC diagnostics demands further investigation. However, the variable tracer uptake of ACC and the necessity to acquire high-quality morphological images for the detection of perineural tumor spread impede the introduction of 18 F-FDG PET/CT. 15 Nevertheless in case of suspected recurrence, it is anticipated that metabolic information provided by 18 F-FDG PET could improve the distinction between benign and malignant lesions. 16 However, ACC patients might benefit from the implementation of integrated PET/MRI in the follow-up workflow by combining the acquisition of functional information on glucose metabolism with high-quality morphological MRI in one single examination. 17 Thus, the aim of our study was to evaluate if combined 18 FDG-PET/MRI is superior to MRI in the detection of tumor recurrence of adenoid cystic carcinoma in patients undergoing surveillance monitoring after initial treatment.
| PATIENTS AND METHODS

| Patients
This study was approved by the institutional review board (study number 11-4822-BO). All patients underwent a clinically indicated whole-body 18 F-FDG PET/CT and subsequently an additional PET/MRI of the head and neck area after informed written consent was obtained. PET/CT examinations were performed for surveillance purposes after initial treatment of histopathologically confirmed adenoid cystic carcinoma. The range between primary diagnosis and tumor relapse was 1-22 years (mean time 6.9 years).
A total of 32 examinations performed in 10 patients (mean age 59 AE 10 years; range 32-79 years at the time of examination) met the inclusion criteria of corresponding clinical examination, cross-sectional imaging follow-up, or histopathology and were enrolled in the final analysis. PET acquisition was performed in list mode for 20 minutes of the head and neck area and PET images were reconstructed using the iterative ordered-subset expectation maximization algorithm, 3 iterations and 21 subsets, a Gaussian filter with 4 mm full width at half maximum and a 344 × 344 image matrix.
| PET/MRI
The following sequences were acquired using a dedicated 20-channel radiofrequency coil for the head and neck region during PET acquisition: 
| Image analysis
The imaging datasets of the 18 F-FDG PET/MRI examinations were analyzed in random order by two experienced readers in MRI and hybrid imaging on a dedicated OsiriX Workstation (Pixmeo SARL, Bernex, Switzerland) in separate reading sessions. In a first reading session, each reader evaluated the MRI dataset described above only. In a second reading session, with a minimum of 4 weeks apart to avoid recognition bias, the complete 18 F-FDG PET/MRI dataset, including PET was evaluated. To enable a dedicated analysis of the diagnostic accuracy of MRI and 18 F-FDG PET/MRI, on the one hand, and imitate the workflow in clinical every day work, on the other hand, the following algorithm was applied: initially, the readers were aware of all available clinical information and the clinical indication of the scan. The results of prior or follow-up imaging were unavailable to avoid recognition bias. But as false-positive findings caused by tissue distortion and scar tissue from radiation and surgery can obscure detection of recurrence or even imitate tumorous tissue due to increased 18 F-FDG uptake, the comparison with prior imaging examinations is key to a correct diagnosis. 18, 19 To reduce the number of false-positive findings, prior imaging examinations were made available to the reader in case of suspicious findings.
The maximum diameter of all suspicious lesions was determined and the maximum standardized uptake value (SUV max ) was measured by placing a manually drawn polygonal region of interest over each lesion on attenuationcorrected PET images. To evaluate lesion size, the maximum diameter was measured on transverse contrast-enhanced T1-weighted images. If these images were inconclusive due to motion artifacts, transverse T2-weighted images were used. On MRI, focal soft tissue increase and increased contrast agent uptake were considered as a sign of malignancy. Morphological signs of malignancy in lymph nodes comprised (1) increased short axis diameter (>10 mm), (2) central necrosis, (3) irregular shape, and (4) the lack of a fatty hilus sign, and (5) increased contrast agent uptake. 20 In 18 F-FDG PET/MRI, increased 18 F-FDG uptake compared to background was considered as sign of malignancy in fused images. In accordance with previous publications reporting the superiority of PET uptake over morphology 21 as well as the high sensitivity for detection of malignant lesions in MRI, a consensus decision among the two readers was made based on all available data in case of discrepant findings on PET and MR datasets as well as in case of discrepancies between the two readers.
| Reference standard
The reference standard was determined on a per lesion-and per scan-basis, taking into account all available data, including results of prior examinations, follow-up imaging, clinical F-FDG PET/MRT: n = 7).
| Statistical analysis
Statistical analysis was performed using IBM SPSS version 22 (IBM Inc, Armonk, New York) and Graphpad Prism 7 (GraphPad Software, La Jolla, California). Data analysis was performed scan-based as well as lesion-based. Data are presented as mean values AE SD. Sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy for the detection of local tumor recurrences and lymph node metastases were calculated on a per lesion basis for MRI and 18 F-FDG PET/MRI, respectively. Staging differences between both the modalities were compared using McNemar's test. Values of P < .05 were considered statistically significant.
| RESULTS
PET/MRI was successfully completed in all 32 examinations.
Based on the 32 examinations, adenoid cystic carcinoma arising from the base of tongue was diagnosed in 14 patients, from the parotid gland and the trachea, respectively in 6 patients, from the sublingual glands in 3 patients, from the cheek in 2 patients, and from the sinus maxillaris in 1 patient. Primary treatment of the patients included tumor resection, classic radiotherapy as well as high linear energy transfer beams (fast neutrons or carbon ions) or brachytherapy as well as combined therapy, including operation and radiotherapy. The mean time interval between last therapeutic intervention and FDG PET/MRI was 3.2 years (range 60 days to 22 years). According to the reference standard, tumor recurrence was present in 20 cases (62.5%). Mean SUV max across all malignant lesions was 7.1 AE 3.7 (range 2.1-18.3). 18 F-FDG PET/MRI correctly identified all cases with tumor recurrence (100%), whereas MRI correctly identified 19 out of the 20 cases (95%). In this case, lymph node metastases were falsely interpreted as reactive lymph nodes in MRI. In 18 F-FDG PET/MRI, two patients (17%) were classified as false positive, in one case due to a lymph node with elevated FDG uptake (SUV max 4.8; Figure 1 ) and in another case due to misinterpretation of posttherapeutic alterations as local recurrence (SUV max 6.5) without confirmation in subsequently performed clinical examination and in follow-up. In MRI, 1 case (8%) was classified as false positive due to misinterpretation of a lymph node. Perineural tumor spread was observed in four cases, equivocal diagnosed in MRI and For the lesion-based analysis, a total of 79 lesions were included. According to the reference standard, 47 lesions (59.5%) were considered as malignant and 32 (40.5%) as benign (see Table 1 & 2) . Sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy were 96%, 84%, 90%, 93%, and 91% for 18 F-FDG PET/MRI and 77%, 94%, 95%, 73%, and 84% for MRI. Lesion-based diagnostic accuracy of PET/MRI was significantly higher in comparison to MRI (P < .005).
| DISCUSSION
This study demonstrates the feasibility and high diagnostic accuracy of 18 F-FDG PET/MRI in detecting tumor recurrence and locoregional lymph node metastases in patients with adenoid cystic carcinoma of the head and neck and its superiority in comparison to MRI alone (Figure 2) .
Because of the diffuse growth pattern of ACC and posttherapeutic scar formation, the detection of tumor recurrence is challenging, especially as the low soft tissue contrast of contrast-enhanced CT or ultrasound examinations leads to a low diagnostic accuracy. 22, 23 Hence, MRI is considered as superior in clinical routine due to its high soft-tissue contrast. 24, 25 But as surgery and/or radiotherapy may cause significant alterations of tissue anatomy, exclusive morphological information offered by MRI may be insufficient to differentiate between posttherapeutical changes and tumor relapse. Hence, additional functional imaging biomarkers might be helpful. Recent data have demonstrated the added value of metabolic information in detecting adenoid cystic carcinoma 26 as well as the ability of 18 F-FDG PET to detect metastases in lymph nodes that are inconspicuous in morphologic imaging in a variety of cancers. 16 However, clinical studies evaluating the added value of 18 F-FDG PET in ACC are few.
27,28
Park et al. investigated the diagnostic potential of 18 F-FDG PET/CT and contrast-enhanced (ce) CT in patients with salivary glands malignancies in 67 patients and about quarter of them suffering from adenoid cystic carcinoma. 28 In this heterogeneous cohort consisting of patients suffering from different cancer types in different disease and treatment stages, the authors confirmed the benefit of hybrid imaging over conventional imaging alone.
Although 18 F-FDG PET/CT and potentially PET/MRI play a vital part in recurrence diagnostics in squamous cell cancer of the head and neck, 17, 29, 30 the role of hybrid imaging in the diagnosis of recurrent ACC has not been investigated until now. Thus, we investigated the diagnostic potential of 18 F-FDG PET/MRI compared to MRI, the current state of the art modality, in recurrence diagnostics of ACC.
This publication comprises two main messages we believe to be important: first, 18 F-FDG PET/MRI shows a significant higher overall diagnostic accuracy compared to MRI alone in detection of tumor recurrence in patients with adenoid cystic carcinoma. Second, there are particularly 31 Especially concerning the negative predictive value, 18 F-FDG PET/MRI outperforms MRI. Although a high diagnostic accuracy has to be aspired in general, patients under surveillance have an increased a priori probability for malignancies and, therefore, a reliable exclusion of tumor recurrence is of utmost importance for further patient management.
Our study is not without limitations. First, our study includes a heterogeneous group of primary origin of adenoid cystic carcinoma. Thus, a dedicated evaluation of different subtypes would have been desirable, yet difficult to achieve based on the rare nature of the disease. Second, although histopathological sampling for primary tumor was available in all patients, not every detected (metastatic) lesion could be sampled due to ethical reasons and in accordance with current clinical guidelines. Hence, as published in numerous previous trials on hybrid imaging, a modified reference standard was applied to overcome this limitation. 32, 33 In conclusion, this is the first study investigating the performance of 18 F-FDG PET/MRI for the detection of local tumor recurrence and locoregional metastases in patients with ACC. The presented data show a very high diagnostic accuracy of 18 F-FDG PET/MRI on a per lesion basis. Furthermore, 18 F-FDG PET/MRI was shown to be superior to sole MRI in diagnostic accuracy in general and especially concerning its negative predictive value. Thus, 18 F-FDG PET/MRI may play a crucial role for the diagnostic workup of patients in follow-up after primary therapy of adenoid cystic carcinoma in the future.
